Sunday, October 2, 2022
HomeLatest NewsQuality NewsFDA approves new flu treatment

FDA approves new flu treatment

The Food and Drug Administration (FDA) has approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. “This is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years. With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effective treatment alternatives is critical,” said FDA Commissioner Scott Gottlieb, MD.

Stay Connected

Unified Voice Newsletter

Events This Month

october

04oct11:00 am12:00 pmPlaying to Your Strengths - Part 1SDAHO Webinar11:00 am - 12:00 pm Event Type :Education Events,Webinar

05oct11:00 am12:00 pmNo Surprises Act: Are you Ready for 2023?SDAHO Webinar11:00 am - 12:00 pm Event Type :Education Events,Webinar

06oct9:00 am3:00 pmFocus on the Medication AideAvera Education & Staffing Solutions9:00 am - 3:00 pm

06oct11:00 am12:00 pmKey Strategies in Developing Policies and ProceduresSDAHO Webinar11:00 am - 12:00 pm Event Type :Education Events,Webinar

06oct12:00 pm1:00 pmLeverage Data to Hold Payers AccountableAHA Webinar12:00 pm - 1:00 pm Event Type :Education Events,Webinar

X


By submitting this form, you are consenting to receive marketing emails from: SDAHO, 3708 W Brooks Place, Sioux Falls, SD, 57106, http://sdaho.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact